We wanted to compare the Assisted Reproductive Technology (ART) outcomes between two protocols of induction of ovulation in patients with Hypogonadotropic Hypogonadism. In the beginning, all patients receive Recombinant Follicle Stimulating Hormone (Gonal-F) and Recombinant Luteinizing Hormone (Luveris). When at least one follicle reaches 14 mm in diameter, Luveris alone is administered for group A and both drugs Gonal-F and Luveris for group B. Finally Assisted Reproductive Technology (ART) results are compared between the two groups.
In this single blind randomized clinical trial, 90 women with a clinical history of hypogonadotrophic hypogonadism who stopped any treatment with gonadotrophins \>1 month before study, with a negative progesterone challenge test, low serum gonadotrophins (Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) less than 5.0 IU/l) and oestradiol (less than 100 pg/ml) and normal serum concentrations of thyroid stimulating hormone (TSH), testosterone and prolactin within 6 months before the start of treatment are studied in the Royan Institute. Other causes of infertility are excluded from the study. All patients receive treatment with recombinant follicle stimulating hormone (Gonal-F) and recombinant luteinizing hormone (Luveris). When at least one follicle reaches 14 mm in diameter, 4mg/day oestradiol is administered and patients are randomly divided into two groups: Luveris alone (intervention group) and continued treatment with both drugs Gonal-F and Luveris (control group). When at least one follicle detects a mean diameter of ≥18 mm and serum estradiol level reaches 500-2000 pg/ml, ovarian stimulation is stopped and injection of 10000 IU Human Chorionic Gonadotrophin (hCG) is administrated. At the end, the number and size of ovarian follicles, endometrial thickness on the day of injection of Human Chorionic Gonadotrophin (hCG), the number of oocytes retrieved, the number of good quality embryos, chemical and clinical pregnancy rate, fertilization rate and implantation rate will be compared between the two groups.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
90
Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
Administration of (rFSH) and (rLH)
Royan Institute
Tehran, Iran
RECRUITINGnumber of follicles
Evaluation thre number follicles before injection of Human Chorionic Gonadotrophin (hCG)
Time frame: baseline
Size of follicle
Evaluation the size of follicle before injection of Human Chorionic Gonadotrophin (hCG)
Time frame: baseline
Endometrial thickness
Evaluation the endometrial thickness at the day of injection of Human Chorionic Gonadotrophin (hCG)
Time frame: 1day
number of oocytes retrieved
Evaluation the number of oocytes retrieved 34-36 hours after Human Chorionic Gonadotrophin (hCG) injection
Time frame: 3 days
Fertilization rate
Evaluation the fertilization rate 2-3 days before the embryo transfer
Time frame: 2 days
Biochemical pregnancy rate
Evaluation the biochemical pregnancy rate 2 weeks after embryo transfer
Time frame: 2 weeks
Clinical pregnancy rate
Evaluation the clinical pregnancy rate 4-6 weeks after embryo transfer
Time frame: 4 weeks
Implantation rate
Evaluation the implantation rate 4-6 weeks after embryo transfer.
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.